Skip to main content
Equibles
MAZE logo

MAZE · Maze Therapeutics, Inc.

Track MAZE — free

Use MAZE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MAZE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$25.91 -0.52 (-1.97%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.45B
Shares
55.55M
Volume · Oct 5 588.01K Avg daily vol (3M) 564.21K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$26.43 Open$26.67 Day$25.78–27.03 52W close$22.39–51.84 Avg vol 30d725K Short int5.7M · 10.2% float · 10.4d Short vol81% Last earningsMar 25, 2026 DataJan 2025–Oct 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.50M
Trailing 12 months
Net income (TTM)
−$133.59M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
34.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$372.13M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+34.7%
Year over year · more shares
Price change (1Y)
-0.3%
Trailing year
Short interest
10.2%
Latest settlement · 10.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −20%
below
Price vs 50-day avg −2%
below
RSI (14) 50
neutral
MACD trend Positive
52-week position 14%
near low
Momentum
relative strength
Very Weak
1-month return +1%
trailing
6-month return −5%
trailing
YTD return −36%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $27 › 200d $33 — 200d above 50d
Institutional flow Accumulating
1 of 162 funds reported for Sep 30 · net +202 sh shares · +1 new
Insider flow Distributing
Net -$1.1M over 90 days · 100% sells
Short interest Falling
10.22% of float · ▼ -4.1% MoM · 10.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
162 holders — mid 1-yr range
Squeeze score 62
elevated · 0–100
Fundamentals
Poor
EPS growth −344%
Y/Y
Free cash flow $-112.7M
Quant / Vol
risk profile
Very High
Volatility 67%
annualized · 1-yr
Max drawdown −57%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
−2% Neutral
RSI (14)
50 Neutral
MACD trend
Positive Bullish
52-week position
14% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $27 › 200d $33 — 200d above 50d
Institutional flow Accumulating
1 of 162 funds reported for Sep 30 · net +202 sh shares · +1 new
Insider flow Distributing
Net -$1.1M over 90 days · 100% sells
Short interest Falling
10.22% of float · ▼ -4.1% MoM · 10.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
162 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $22 Now $26 · 14% Range high $52
vs 200-day avg -20% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MAZE
Maze Therapeutics, Inc.
this stock
$1.45B -36.2% — — 10.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
163
% held
105.6%
Reported
1 of 162
Top holder
Frazier Life Sciences Man…
Held Float
View
Held by Funds
Fund positions
176
View
Short & Settlement
Short Interest Falling
Shares short
5.7M
Days to cover
10.4d
Change
-240.0K sh
View
Short Volume
Short vol %
81%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
1.0K
Value
$27.3K
As of
Sep 2, 2026
View
Off-Exchange
Off-exchange %
41.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.1M
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$167.5M
Net income (FY)
$-131.1M
EPS diluted
$-3.05
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 9, 2026
This year
15
View
Proposed Sales
Value
$438.7K
Shares
16.1K
Filed
Oct 1, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 9, 2026
View

Performance

5D 20D 120D MTD YTD
MAZE -1.6% +0.8% -4.5% -2.8% -36.2%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY -2.8% +0.2% -16.1% -4.4% -49.8%
Key facts CIK 1842295 CUSIP 578784100 13F (30d) 3 filings 3 filers Visit website Investor relations